Navigation Links
Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Date:9/10/2007

well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases are intended to identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the value and use of data to be produced in the Phase 1 trial; the timing of announcing data from the Phase 1 trial; the launching of a Phase 2 clinical trial in CIN patients; the possibility of a second Phase 2 trial in HIV-positive CIN patients; the design of the Phase 1 trial; and the collection and use of immunological data to indicate efficacy of the compound.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials and the possibility that the results
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 Ontotext S4 ... by Ontotext . Now the same enterprise ... of structured and unstructured data is available to start-ups ... of enterprise technology. Organizations that do not have resources ... management can use S4 since there is no need ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... , , EMERYVILLE, Calif. , Feb. ... announced that it has appointed Ted W. Love , M.D., ... Michael Kauffman , M.D., Ph.D., who has served as Interim ... Chief Medical Officer reporting to Dr. Love.   , In his ...
... , , , , ... Cellectricon AB today,announced that it has resumed its litigation against ... in the United States,District Court for the Northern District ... patents issued or licensed to Cellectricon for,microfluidic technology used ...
... ... Discussion on Boston Biotech Trends and Developments, , ... Boston, MA (PRWEB) January 30, 2010 -- Caturano and Company will host ... Biotech 2010 and Beyond , on Wednesday, February 3, 2010 at their office in Charlestown, ...
Cached Biology Technology:Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development 2Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development 3Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development 4Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development 5Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences 2Caturano and Company to Host Boston Biotech Event, "BIBA Biotech 2010 and Beyond" 2
(Date:8/21/2014)... smog-producing toxins in past decade, GTA still violates ... that while the Greater Toronto Area (GTA) has ... to smog, the city continues to violate the ... can cause or aggravate health problems such as ... a set of complex photochemical reactions involving volatile ...
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... but they are the ultimate source of all organic ... dependent on algae, too, to suck up climate-warming carbon ... bottom of the ocean. Now, by using a combination ... showing that viruses infecting those algae are driving the ... else stays essentially the same, and this has important ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Viruses take down massive algal blooms, with big implications for climate 2
... JISC Collections has purchased the archive content of ... protocols. With immediate effect the SpringerProtocols archive content ... of charge to UK Higher and Further Education ... than 31,000 protocols, most of which come from ...
... , May 2, 2013 CDX Diagnostics, Inc ... ), filed a patent infringement action against Histologics, LLC, ... Pathology, LLP d/b/a Avero Diagnostics (collectively, "Defendants") in the ... New York . According to court ...
... New discoveries of the way plants transport important substances ... pests, increase salt and drought tolerance, control water loss ... the supply of food and energy for our rapidly ... 12 leading plant biologists from around the world whose ...
Cached Biology News:JISC Collections purchases SpringerProtocols 2Shared Medical Resources, LLC files suit against Histologics, LLC, Women's Health Laboratories and Avero Diagnostics for Willful Patent Infringement 2New plant protein discoveries could ease global food and fuel demands 2New plant protein discoveries could ease global food and fuel demands 3New plant protein discoveries could ease global food and fuel demands 4
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
Biology Products: